Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 10, 2007, Pages 1224-1232

  Isidori, Alessandro ^a,b   Motta, Maria Rosa ^a   Tani, Monica ^a   Terragna, Carolina ^a   Zinzani, Pierluigi ^a   Curti, Antonio ^a   Rizzi, Simonetta ^a   Taioli, Simona ^a   Giudice, Valeria ^c   D'Addio, Alessandra ^a   Gugliotta, Gabriele ^a   Conte, Roberto ^c   Baccarani, Michele ^a   Lemoli, Roberto M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAN SALVATORE HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Autologous stem cell transplantation; CD133+ cells; CD34+ cells; Chronic lymphocytic leukemia; Positive selection; Purging

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIINFECTIVE AGENT; BUSULFAN; CD133 ANTIGEN; CD19 ANTIGEN; CD34 ANTIGEN; CD5 ANTIGEN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; NYSTATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ANTIGEN PURIFICATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CD34 SELECTION; CELL FRACTIONATION; CELL SELECTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DISEASE COURSE; DRUG MEGADOSE; ENGRAFTMENT; FEMALE; FOLLOW UP; HUMAN; IMMUNOMAGNETIC SEPARATION; INFECTION; LEUKAPHERESIS; LEUKEMIA CELL; LEUKEMIA REMISSION; LIVER DISEASE; LYMPHOPOIESIS; MALE; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; MYELOPOIESIS; STEM CELL MOBILIZATION; T CELL DEPLETION; TREATMENT RESPONSE;

ANTIGENS, CD; BONE MARROW PURGING; CELL SEPARATION; CHRONIC DISEASE; FEMALE; GLYCOPROTEINS; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PEPTIDES; PILOT PROJECTS; PLURIPOTENT STEM CELLS; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 34548669612     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.07.004     Document Type: Article

References (40)

1. Miraglia S., Godfrey W., Yin A.H., et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization and molecular cloning. Blood 90 (1997) 5013
2. Yin A., Miraglia S., and Zanjiani E.D. AC 133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90 (1997) 5002
3. Bathia M. AC 133 expression in human stem cells. Leukemia 15 (2001) 1685-1688
4. Matsumoto K., Yasui K., Yamashita N., et al. In vitro proliferation potential of AC 133 positive cells in peripheral blood. Stem Cells 18 (2000) 196-203
5. +cells selected from high-risk breast cancer. Neoplasma 47 (2000) 73-80
6. Kocher A.A., Schuster M.D., Szabolcs M.J., et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7 (2001) 430-436
7. Gill M., Dias S., Hattori K., et al. Vascular trauma induces rapid but transient mobilization of VEGFR2+AC133+ endothelial precursors cells. Circ Res 88 (2001) 167-174
8. + cells identifies a population of functional endothelial precursors. Blood 95 (2000) 952-958
9. Kaufman D.S., Hanson E.T., Lewis R.C., Auerbach R., and Thomson J.A. Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 98 (2001) 10716-10721
10. Kelly S., Bliss T.M., Shah A.K., et al. Transplanted human fetal neural stem cells survive, migrate and differentiate in ischemic rat cerebral cortex. Proc Natl Acad Sci USA 101 (2004) 11839-11844
11. - stem cells that give rise to SCID-repopulating cells. Blood 101 (2003) 869-876
12. Jiang Y., Jahagirdar B.N., Reinhardt R.L., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418 (2002) 41-49
13. + selected progenitor cells from alternative donors. Br J Haematol 124 (2004) 72-79
14. Bitan M., Shapira M.Y., Resnick I.B., et al. Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133+-purified stem cells. Exp Hematol 33 (2005) 713-718
15. Barfield R.C., Hale G.A., Burnette K., et al. Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acute lymphoblastic leukemia. Pediatr Blood Cancer 48 (2007) 349-353
16. Diehl L.F., Karnell L.H., Menck H.R., et al. The American College of Surgeons Commission on Cancer and The American Cancer Society. The National Cancer Data Base report on age, gender, treatment and outcomes of patients with chronic lymphocytic leukemia. Cancer 86 (1999) 2684
17. Montillo M., Hamblin T., Hallek M., Montserrat E., and Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 90 (2005) 391-399
18. Rai K.R., Peterson B.L., Appelbaum F.R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 24 (2000) 1750-1756
19. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine: results of a large international study. Blood 99 (2002) 3554-3561
20. Rai K.R., Freter C.E., Mercier R.J., et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20 (2002) 3891-3897
21. Faderl S., Coutrè C., Byrd J.C., et al. The evolving role of Alemtuzumab in management of patients with CLL. Leukemia 19 (2005) 2147-2152
22. Michallet M., Archimbaud E., Bandini G., et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med 124 (1996) 311-315
23. Khouri I.F., Keating M., Korbling M., et al. Transplantlite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16 (1998) 2817-2824
24. Sorror M.L., Maris M.B., Sandmaier B.M., et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 19 (2005) 3819-3829
25. Dreger P., Brand R., Milligan D., et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 19 (2005) 1029-1033
26. Gribben JG. Salvage therapy for CLL and the role of stem cell transplantation. Hematol Am Soc Hematol Educ Program. 2005;292-298.
27. Rabinowe S.N., Soiffer R.J., Gribben J.G., et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 82 (1993) 1366-1376
28. Gribben J.G., Zahrieh D., Stephans K., et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106 (2005) 4389-4396
29. Milligan D., Fernandes S., Dasgupta R., et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 105 (2005) 397-404
30. Dreger P., Viehmann K., von Neuhoff N., et al. A prospective study of positive/negative ex vivo B-cell depletion in patients with chronic lymphocytic leukemia. Exp Hematol 28 (2000) 1187-1196
31. Altes A., Sierra J., Esteve J., et al. CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections. Exp Hematol 30 (2002) 824-830
32. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (1994) 1361-1392
33. + cells to support single or tandem high-dose chemotherapy. Blood 95 (2000) 2234-2239
34. Lemoli R.M., de Vivo A., Damiani D., et al. Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective to support myeloablative chemotherapy in patients with hematological malignancies and poor peripheral blood stem cell mobilization. Blood 102 (2003) 1595-1600
35. + cells to remove circulating myeloma cells. Blood 87 (1996) 1625-1634
36. Martinelli G., Terragna C., Zamagni E., et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 18 (2000) 2273-2281
37. + peripheral progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 24 (1999) 1329-1336
38. Dreger P., Viehmann K., von Neuhoff N., et al. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery. Bone Marrow Transplant 24 (1999) 153-161
39. + cells of patients with B-cell chronic lymphocytic leukemia. Blood 89 (1997) 4275-4281
40. Ghan B., Wendenburg B., Troff C., et al. Analysis of progenitor cell involvement in B-CLL by simultaneous immunophenotypic and genotypic analysis at the single cell level. Br J Haematol 105 (1999) 955-959